CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Boston Pharmaceuticals , a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced positive results from a Phase 2 study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). Treatment with efimosfermin led to

Both ECC4703 and ECC0509 demonstrated best-in-class potential, with favorable safety and tolerability profiles, clear target engagement and encouraging efficacy signalsBOSTON and SHANGHAI, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that two late-breaking abstracts on new Phase 1 data covering its novel oral THR-β full a

Normann Fichtner, market development director, AM at Nano Dimension, looks at the rapidly growing use of AM within the world of medical devices. As we navigate a world increasingly focused on personalised medicine, digital health and smart healthcare solutions, advanced technologies such as 3D printing are no longer a novelty, but a core pillar of daily operations for medical professionals across the globe. While applications are still evolving at rapid pace, the introduction of AM is already re

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 2024 and in the U.K. in October 2024 PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE® study at the American Association f

FOSTER CITY, Calif.--( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi ® (seladelpar) achieved a composite biochemical response (CBR), demonstrating significant improvements in a key measures of PBC progression. Additionally, 41% (15 out of 37) of participants achieved normal

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome Pemvidutide is currently being evaluated in IMPACT, the Phase 2b trial in subjects with MASH; data readout expected in Q2 2025 GAITHERSBURG, Md., Nov. 15, 202

A positive recommendation for screening would expand access to T1D early detection and incorporate it into routine medical care NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Today Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization announced a campaign to secure a recommendation for T1D screening from the United States Preventive Services Task Force (USPSTF). If obtained, such a positive recommendation would require all insurance plans to cover

CHICAGO--( BUSINESS WIRE )--Vektor Medical, a leader in non-invasive arrhythmia analysis and localization, announced today the presentation of new data showcasing the significant capabilities of vMap, its AI-powered solution for enhancing cardiac arrhythmia treatment. To be presented on November 17 at the American Heart Association (AHA) Scientific Sessions 2024, this data highlights vMap’s impressive 91.1% accuracy rate in differentiating epicardial from endocardial ventricular tachycardia, out

NEW YORK--( BUSINESS WIRE )-- OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported financial results for the third quarter of 2024 ended September 30, 2024 and provided a business update. “The third quarter was pivotal for OS Therapies as we completed our initial public offering and finished dosing the final patient enrolled in our Phase 2b clinical trial of OST-HER2 in resecte

Three major investors are calling on Smith+Nephew to explore breaking up parts of its business with a focus on potentially spinning off its orthopedics division, Financial Times reports. The shareholders, who rank among the company’s top 20 investors, told the Financial Times that Smith+Nephew should divest its orthopedics unit if it fails to show significant improvement. Two investors suggested that a private equity buyer could be interested in the orthopedics division, the largest revenue gene